Antibodies to watch in 2026
Thursday 29 January 2026
07:00 [PST] 10:00 [EST] 15:00 [GMT]
In this webinar, presented in association with the journal mAbs, Drs. Crescioli and Reichert discuss recent trends in antibody therapeutics development and forecast key events that may occur in 2026.
They will begin with a brief review of approvals from 2025, the product candidates with marketing applications under consideration and investigational antibodies – including bispecifics and antibody-drug conjugates – forecast to enter regulatory review by the end of 2026. They will also discuss benchmarks for the time typically required for clinical development and regulatory review based on recently approved antibody therapeutic products stratified by their therapeutic area, mechanism of action, format and country of origin.
If you are unable to view the form on the page below, you can access it here.
- Trends in antibody therapeutics development
- How investigational early-stage antibody research is being translated into tangible clinical outcomes
- Clinical phase and approval success rates for unconventional antibody formats such as bispecifics and ADCs
- Projections for investigational antibody therapeutics approvals in 2025 and 2026
The annual ‘Antibodies to Watch’ articles published in mAbs from 2010 to 2025 can be found here.
-
Antibody enthusiasts
-
Research scientists
-
Strategic intelligence experts
-
Portfolio managers
Silvia Crescioli
Independent Consultant
Silvia Crescioli is an independent consultant specializing in business intelligence and science communication for antibody therapeutic research and development, applying her background in antibody engineering and cancer immunology to support innovation and informed decision-making. Since 2021, she has co-authored the annual ‘Antibodies to Watch’ articles in mAbs. She earned her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence (Italy) in 2014 and held a postdoctoral position at King’s College London (UK) until 2023, where she is now a Visiting Research Fellow.
Janice Reichert
Editor-in-Chief
mAbs
Janice Reichert is an internationally recognized expert in the development of antibody therapeutics. She is Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania (PA, USA) and did her post-doctoral training at Harvard Medical School (MA, USA).
In association with
